Nivolumab versus investigator’s choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age

OBJECTIVES: Many patients with squamous cell carcinoma of the head and neck (SCCHN) are ≥65 years old; comorbidities and other age-related factors may affect their ability to tolerate traditional chemotherapy. Nivolumab is the only immunotherapy to significantly improve overall survival (OS) versus...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oral Oncol
Главные авторы: Saba, Nabil F., Blumenschein, George, Guigay, Joel, Licitra, Lisa, Fayette, Jerome, Harrington, Kevin J., Kiyota, Naomi, Gillison, Maura L., Ferris, Robert L., Jayaprakash, Vijayvel, Li, Li, Brossart, Peter
Формат: Artigo
Язык:Inglês
Опубликовано: 2019
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7723820/
https://ncbi.nlm.nih.gov/pubmed/31422216
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.oraloncology.2019.06.017
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы